Journal
JOURNAL OF CONTROLLED RELEASE
Volume 240, Issue -, Pages 332-348Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2016.01.020
Keywords
Nanoparticle; Liver; Hepatobiliary clearance; Macrophage
Funding
- Canadian Institute of Health Research (CIHR) [MOP-130143, RMF-111623]
- Natural Sciences and Engineering Research Council (NSERC) [2015-06397]
- Prostate Cancer Canada [D2014-12]
- CIHR [GCS 105653-1]
- Ministry of Training Colleges and Universities
- Wildcat Foundation
- University of Toronto
- NSERC
- Cecil Yip Doctoral Research Award
- Barbara & Frank Milligan Graduate Fellowship
- CIHR Frederick Banting and Charles Best Canada graduate scholarship
Ask authors/readers for more resources
30-99% of administered nanoparticles will accumulate and sequester in the liver after administration into the body. This results in reduced delivery to the targeted diseased tissue and potentially leads to increased toxicity at the hepatic cellular level. This review article focuses on the inter-and intra-cellular interaction between nanoparticles and hepatic cells, the elimination mechanism of nanoparticles through the hepatobiliary system, and current strategies to manipulate liver sequestration. The ability to solve the nanoparticle-liver interaction is critical to the clinical translation of nanotechnology for diagnosing and treating cancer, diabetes, cardiovascular disorders, and other diseases. (C) 2016 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available